EconTalk Robin Feldman on Drug Patents, Generics, and Drug Wars
13 snips
Jun 26, 2017 Robin Feldman, an expert in drug patents and generics from the University of California Hastings College of Law, discusses the tactics employed by pharmaceutical companies to reduce competition from generic drugs. Topics include the Hatch-Waxman Act, weak patents, pay for delay settlements, evasion of price controls, complexities of drug pricing, and challenges in replacing branded drugs with ineffective capsules.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7
Introduction
00:00 • 4min
The Problem of Weak Patents
04:23 • 16min
Examining the Argument for Pay for Delay Settlements
20:21 • 2min
Generations of Techniques to Delay Generic Competition
22:33 • 3min
Analyzing Evasion of Price Controls and Regulatory Arbitrage in the Drug Industry
25:09 • 13min
The Complexities of Drug Pricing and Exploitation
37:47 • 2min
Challenges in Replacing Branded Drugs with Ineffective Capsules
39:56 • 25min